Login
Need to Register?   Forgot Password?
You need to upgrade your Flash Player to view this content.



What's New?
  • New CME-certified case study!
    The Role of Nonpharmacologic and Lipid-Lowering Therapies in a Patient With Low Framingham-Assessed Cardiovascular Risk. M. Dominique Ashen, PhD, CRNP, and CCMD Faculty Member Roger S. Blumenthal, MD, explore nonpharmacologic and lipid-lowering treatments for a patient with evidence of increased cardiovascular risk beyond that suggested by Framingham Risk Scoring. Earn 0.75 AMA PRA Category 1 Credit™ and access to an anthology of CCMD slides instantly!
  • CMDManagement™ Fall 2008 issue now available for CME credit!
    This issue of our award-winning newsletter explores the assessment of CVD risk using nontraditional risk factors. Also featured: a case study by Erin Michos, MD, MHS, exploring cardiovascular risk stratification in women and younger adults, and a patient handout focusing on managing risk factors for stroke.
  • FDA Alert: Simvastatin With Amiodarone Increases Risk of Rhabdomyolysis
    On August 8 ,2008, the FDA released a warning regarding reports of increased rhabdomyolysis risk from concomitant use of simvastatin greater than 20 mg qd and amiodarone, an arrhythmia treatment for controlling life-threatening recurrent ventricular arrhythmias. In its alert, the FDA noted that all statins have a potential risk of rhabdomyolysis, whether or not they are administered with amiodarone, but the risk is more prominent when used with the arrhythmia agent.
  • OnsiteInsight® from AHA Scientific Sessions 2008!
    This issue of OnsiteInsight® highlights clinical-trial results and scientific sessions focusing on issues in the management of atherosclerosis from the American Heart Association Scientific Sessions 2008 in New Orleans! Also featured: expert commentary from CCMD Education Council Member JoAnne M. Foody, MD.
  • NDEI.org Interactive Case Study
    NDEI Faculty Member Mark W. Stolar, MD, discusses management of a 47-year-old Hispanic man with type 2 diabetes who presents with sleep apnea and occult depression
  • Slides of the Month
     
    JPAD: Study Design
    The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) tria...
    JPAD Results: Primary Endpoint (CVD Composite)
    The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) tria...
    JPAD Results: Primary Endpoint in Subgroups
    The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) tria...
    JUPITER: Study Design
    The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating...
    JUPITER Results: Primary Endpoint
    The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating...
    JUPITER Results: Components of Primary Endpoint
    The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating...
    JUPITER Results: Summary
    The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating...
    JUPITER: Lipid and Hs-CRP Levels
    The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating...
    In the News
    Controlling Type 2 Diabetes With Low-Carb Diets
    Jan 06, 2009 -- In a six-month comparison of low-carb diets, one that encourages eating carbohydrates with the lowest-possible rating on the glycemic index leads to greater improvement in blood sugar control, according to Duke University Medical Center researchers.

    Genetic Variation May Lead To Early Cardiovascular Disease
    Jan 06, 2009 -- Researchers from Duke University Medical Center have identified a variation in a particular gene that increases susceptibility to early coronary artery disease. For years, scientists have known that the devastating, early-onset form of the disease was inherited, but they knew little about the gene(s) responsible until now. The results are published January 2 in the open-access journal PLoS Genetics.

    Copyright 2009 Medical News Today